阳光肺科

 找回密码
 立即注册

微信扫码登录

搜索

[围术期无驱动] III期N2非小细胞肺癌诱导化免治疗后手术 vs 同期化放疗加免疫治疗:大数据和系统评价

[复制链接]
阳光肺科 发表于 2025-5-26 02:37:37 | 显示全部楼层 |阅读模式
Kumar A, Srinivasan D, Potter AL, Mathey-Andrews C, Lanuti M, Martin LW, Jeffrey Yang CF.Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Jun;167(6):1895-1905.e2. doi: 10.1016/j.jtcvs.2023.09.029. Epub 2023 Sep 16. PMID: 37722622.

Objective: Despite the growing relevance of immunotherapy for non-small cell lung cancer (NSCLC), there is limited consensus on the optimal treatment strategy for locally advanced NSCLC. This study evaluated the overall survival of patients with stage III-N2 NSCLC undergoing induction chemoimmunotherapy with surgery (CT/IO+Surgery) and definitive concurrent chemoradiation followed by immunotherapy (cCRT+IO).
Methods: Patients with cT1-3, N2, M0 NSCLC in the National Cancer Database (2013 to 2019) were included and stratified by treatment regimen: CT/IO+Surgery or cCRT+IO. Overall survival was evaluated using Kaplan-Meier analysis, Cox proportional hazards modeling, and propensity score matching on 10 prognostic variables.
Results: Of the 3382 patients who met the study eligibility criteria, 3289 (97.3%) received cCRT+IO and 93 (2.8%) received CT/IO+Surgery. The 3-year overall survival of the entire cohort was 58.2% (95% CI, 56.2% to 60.1%). Multivariable-adjusted Cox proportional hazards modeling demonstrated better survival after CT/IO+Surgery than after cCRT+IO (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.32 to 0.84; P = .007). In a 3:1 variable ratio propensity score-matched analysis of 223 patients who received cCRT+IO and 76 patients who received CT/IO+Surgery, 3-year overall survival was 63.2% (95% CI, 55.9% to 70.2%) after cCRT+IO and 77.2% (95% CI, 64.6% to 85.7%) after CT/IO+Surgery (P = .029).
Conclusions: In this national analysis, multimodal treatment including immunotherapy was associated with a 3-year overall survival rate of 58.2% for all patients with stage III-N2 NSCLC and 77.2% for patients who underwent chemoimmunotherapy followed by surgery. These results should be considered hypothesis-generating and demonstrate the importance of developing a randomized trial to evaluate the role of surgery versus chemoradiation for locally advanced NSCLC in the modern immunotherapy era.


微信扫二维码转发分享

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2025-7-10 05:34

Powered by Discuz! X3.5

© 2001-2025 Discuz! Team.

快速回复 返回顶部 返回列表